ProtoMed: Drugs from soybeans

Having watched the "early commercialization" strategies at a variety of biotech companies, ProtoMed Inc. President and CEO Louis Scotti thinks he's learned something: the strategy of buying in existing products can't be the basis of an entire company, and it only works if the price is right.

"When you buy a product by definition you are over-paying," said Scotti. "You can do it to open the door, but if you keep doing it, the pyramid falls apart. You get products with low growth and you haven't added any value."...